Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

ClinicalTrials.gov ID: NCT01386554

Public ClinicalTrials.gov record NCT01386554. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)

Study identification

NCT ID: NCT01386554
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Mallinckrodt; Industry
Enrollment: 60 participants

Conditions and interventions

Conditions

Interventions

Repository Corticotropin Injection Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2011
Primary completion: Nov 20, 2016
Completion: May 4, 2017
Last update posted: Nov 19, 2019

2011 – 2017

United States locations

U.S. sites: 14
U.S. states: 11
U.S. cities: 14

Facility	City	State	ZIP	Site status
Mallinckrodt Investigational Site	Sacramento	California	95825	—
Mallinckrodt Investigational Site	Stanford	California	94304	—
Mallinckrodt Investigational Site	Jacksonville	Florida	32209	—
Mallinckrodt Investigational Site	Atlanta	Georgia	30322	—
Mallinckrodt Investigational Site	Rochester	Minnesota	55905	—
Mallinckrodt Investigational Site	Reno	Nevada	89502	—
Mallinckrodt Investigational Site	New York	New York	10032	—
Mallinckrodt Investigational Site	Chapel Hill	North Carolina	27599	—
Mallinckrodt Investigational Site	Durham	North Carolina	27705	—
Mallinckrodt Investigational Site	Bethlehem	Pennsylvania	18017	—
Mallinckrodt Investigational Site	Charleston	South Carolina	29425	—
Mallinckrodt Investigational Site	Chattanooga	Tennessee	37404	—
Mallinckrodt Investigational Site	Houston	Texas	77030	—
Mallinckrodt Investigational Site	Lubbock	Texas	79430	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01386554, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 19, 2019 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01386554 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →